Tratamiento de la hipertrigliceridemia con icosapento de etilo en pacientes de alto/muy alto riesgo cardiovascular. Documento de consenso de la Sociedad Española de Cardiología y Sociedad Española de Diabetes

[1]  E. Huang,et al.  10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[2]  Deepak L. Bhatt,et al.  Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG , 2021, Circulation.

[3]  Deepak L. Bhatt,et al.  Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL , 2021, Circulation.

[4]  M. Koschinsky,et al.  Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. , 2021, Arteriosclerosis, thrombosis, and vascular biology.

[5]  J. Borén,et al.  Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society , 2021, European heart journal.

[6]  I. V. Van Gelder,et al.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2021, European heart journal.

[7]  Deepak L. Bhatt,et al.  Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry. , 2021, International journal of cardiology.

[8]  C. Ballantyne,et al.  2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2021, Journal of the American College of Cardiology.

[9]  M. Khan,et al.  Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis , 2021, EClinicalMedicine.

[10]  V. Fuster,et al.  Triglycerides and Residual Atherosclerotic Risk , 2021, Journal of the American College of Cardiology.

[11]  W. März,et al.  Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. , 2021, Atherosclerosis.

[12]  G. Francis,et al.  2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. , 2021, The Canadian journal of cardiology.

[13]  R. Arbel,et al.  Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia-Value for Money Analysis. , 2021, The American journal of medicine.

[14]  Sathish Kumar Jayapal,et al.  Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.

[15]  C. Ballantyne,et al.  Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. , 2020, Clinical chemistry.

[16]  D. Mozaffarian,et al.  Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. , 2020, JAMA.

[17]  D. Mauricio,et al.  Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC/EASD: data from a large Mediterranean population. , 2020, European journal of preventive cardiology.

[18]  N. Wong,et al.  Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease. , 2020, Journal of diabetes and its complications.

[19]  Deepak L. Bhatt,et al.  Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies , 2020, European heart journal supplements : journal of the European Society of Cardiology.

[20]  M. Budoff,et al.  Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites , 2020, European heart journal supplements : journal of the European Society of Cardiology.

[21]  N. Wong,et al.  Five-Year Residual Atherosclerotic Cardiovascular Disease Risk Prediction Model for Statin Treated Patients with Known Cardiovascular Disease. , 2020, The American journal of cardiology.

[22]  P. Toth,et al.  Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007–2014 , 2020, American journal of preventive cardiology.

[23]  Deepak L. Bhatt,et al.  Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial , 2020, European heart journal.

[24]  N. Wong,et al.  REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES]). , 2020, The American journal of cardiology.

[25]  M. Davidson.  Reducing residual cardiovascular risk with novel therapies. , 2020, Current opinion in lipidology.

[26]  Deepak L. Bhatt,et al.  Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[27]  K. Ray,et al.  Triglycerides and residual risk. , 2020, Current opinion in endocrinology, diabetes, and obesity.

[28]  A. Mithal,et al.  Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. , 2020, Advances in experimental medicine and biology.

[29]  Deepak L. Bhatt,et al.  Reduction in Revascularization With Icosapent Ethyl , 2020, Circulation.

[30]  P. Austin,et al.  Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. , 2019, European heart journal.

[31]  T. A. Jacobson,et al.  National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. , 2019, Journal of clinical lipidology.

[32]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[33]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[34]  Deepak L. Bhatt,et al.  Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. , 2019, Journal of the American College of Cardiology.

[35]  Deepak L. Bhatt,et al.  Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. , 2019, Journal of the American College of Cardiology.

[36]  L. Masana,et al.  Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019 , 2019, Clínica e Investigación en Arteriosclerosis (English Edition).

[37]  Deepak L. Bhatt.  REDUCE-IT. , 2019, European heart journal.

[38]  J. Manson,et al.  Marine n‐3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer , 2019, The New England journal of medicine.

[39]  Deepak L. Bhatt,et al.  Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia , 2019, The New England journal of medicine.

[40]  E. V. van Beek,et al.  Coronary Artery Plaque Characteristics Associated With Adverse Outcomes in the SCOT-HEART Study , 2019, Journal of the American College of Cardiology.

[41]  P. Libby,et al.  Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study , 2018, American heart journal.

[42]  F. Song,et al.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. , 2018, The Cochrane database of systematic reviews.

[43]  J Wouter Jukema,et al.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018, The New England journal of medicine.

[44]  R. Collins,et al.  Effects of n‐3 Fatty Acid Supplements in Diabetes Mellitus , 2018, The New England journal of medicine.

[45]  K. Reynolds,et al.  Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol , 2018, Diabetes, obesity & metabolism.

[46]  A. Sahebkar,et al.  Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials , 2018, Annals of medicine.

[47]  N. Guijarro,et al.  Population and methodology of the SIMETAP study: Prevalence of cardiovascular risk factors, cardiovascular diseases, and related metabolic diseases , 2018, Clínica e Investigación en Arteriosclerosis (English Edition).

[48]  A. Pandey,et al.  Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine. , 2018, Circulation.

[49]  I. Kubota,et al.  A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. , 2017, Journal of cardiology.

[50]  R. Mason,et al.  Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk? , 2017, Postgraduate medicine.

[51]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[52]  Jennifer G. Robinson,et al.  Determining When to Add Nonstatin Therapy: A Quantitative Approach. , 2016, Journal of the American College of Cardiology.

[53]  C. Ballantyne,et al.  Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. , 2016, Prostaglandins & other lipid mediators.

[54]  S. Yusuf,et al.  Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[55]  R. Jacob,et al.  Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents , 2016, Journal of cardiovascular pharmacology.

[56]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[57]  Sarah Parish,et al.  Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.

[58]  S. Yusuf,et al.  n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. , 2012, The New England journal of medicine.

[59]  E. Ros,et al.  Omega-3 fatty acids and HDL. How do they work in the prevention of cardiovascular disease? , 2012, Current vascular pharmacology.

[60]  D. Mozaffarian,et al.  Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. , 2011, Journal of the American College of Cardiology.

[61]  R. Gomis,et al.  Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study , 2011, Diabetologia.

[62]  J. Saver,et al.  Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. , 2011, Atherosclerosis.

[63]  P. Touboul,et al.  Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis , 2011, Journal of cardiovascular pharmacology.

[64]  H. Drexel,et al.  Combination lipid therapy in type 2 diabetes. , 2010, The New England journal of medicine.

[65]  D. Grobbee,et al.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.

[66]  J. Danesh,et al.  Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.

[67]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[68]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[69]  Y. Matsuzawa,et al.  Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). , 2008, Atherosclerosis.

[70]  Christopher P Cannon,et al.  Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. , 2008, Journal of the American College of Cardiology.

[71]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[72]  Ethan M Balk,et al.  n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. , 2006, The American journal of clinical nutrition.

[73]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[74]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[75]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[76]  J. Pogue,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[77]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[78]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[79]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[80]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[81]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[82]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[83]  D. Alexander,et al.  A Meta‐Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long‐Chain Omega‐3 Fatty Acids and Coronary Heart Disease Risk , 2017, Mayo Clinic proceedings.

[84]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[85]  P. P. Toth.  Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy , 2012 .

[86]  Y. Matsuzawa,et al.  Relationships between plasma fatty acid composition and coronary artery disease. , 2011, Journal of atherosclerosis and thrombosis.

[87]  W. Harris,et al.  n-3 fatty acids and serum lipoproteins: human studies. , 1997, The American journal of clinical nutrition.